Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Li...(esearchers showed that Dioxin one of the...),Health

"We view this study as a landmark event in the development of microRNA based cancer therapeutics" said Amir Avniel, President and CEO of Rosetta Genomics. "While Rosetta's clear focus is on developing diagnostics, this collaborative project with Regulus is an example of how we intend to leverage the tremendous potential that microRNA holds in therapeutics and other domains. Every one of our diagnostic biomarkers is also a potential drug target, and we intend to form strategic alliances with suitable biopharma partners to leverage and commercialize these opportunities."

The data presented at the conference is now available for downloading on the company's website at: http://www.rosettagenomics.com/HCC-study

    The study is supported by a grant from the BIRD foundation.

    [1] Llovet et al., Sorafenib improves survival in advanced Hepatocellular
        Carcinoma (HCC): Results of a Phase III randomized placebo-controlled
        Trial (SHARP trial), Journal of Clinical Oncology, 2007 ASCO Annual
        Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement),
        2007: LBA1

    [2] Health Risks from Dioxin and Related Compounds, National
        Research Council, National Academies Press, 2006

Nexavar(R) (sorafenib) is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art l
'/>"/>